biography
Dr. Nonogaki is a specialist of Diabetes care and Internal medicine. He has obtained PhD in Endocrinology, Metabolism, and Diabetes. Then, he worked as a Postdoc Fellow at the University of California, San Francisco and the Scripps Research Institute, La Jolla. During this period, his research has mainly focused on the role of the central nervous system in the regulation of hepatic glucose production, cytokines and lipid metabolism, and brain serotonin systems and energy homeostasis. He found the novel evidence in the dissociated pathways of serotonin 5-HT2C receptor and leptin in the central regulation of appetite and obesity, and proposed a novel physiological theory of central dissociated regulation of feeding and autonomic neural circuits. Current studies are to determine the physiological mechanisms and potential treatment for obesity, diabetes and their complications. Dr. Nonogaki is also developing novel medical devices for hypertension and diabetes.
Area of Interest
Serotonin network, GLP-1 network, feeding regulation, hepatic glucose and lipid metabolism, and medical device trials for obesity, diabetes, and hypertension.
top publication
1．Nonogaki K, Hazama M, Satoh N. Liraglutide suppresses obesity and hyperglycemia associated with increases in hepatic fibroblast growth factor 21 production in KKAy mice. BioMed Research International 2014 (2014), Article ID 751930, 8 pages.
2．Nonogaki K, Suzuki M. Liraglutide suppresses the plasma levels of active and des-acyl ghrelin independently of active glucagon-like Peptide-1 levels in mice. ISRN Endocrinol. 2013 (2013), Article ID 184753, 5 pages.
3．Nonogaki K. Comment on: Satoh-Asahara et al. Highly purified eicosapentaenoic acid increases interleukin-10 levels of peripheral blood monocytes in obese patients with dyslipidemia. Diabetes Care 2012;35:2631-2639. Diabetes Care. 2013, 36:e109.
4．Nonogaki K, Suzuki M, Sanuki M, Nonogaki N, Takeda K, Tsujita N, Katoh S, and Kubota N. Low-frequency and very low-intensity ultrasound decreases blood pressure in subjects with hypertension. Int J Cardiol, 2013, 168(2):1585-6. doi:pii: S0167-5273(13)00085-5.
5．Kaji T, Nonogaki K. Role of homeobox genes in the hypothalamic development and energy balance. Front Biosci. 18,740-747, 2013.
6．Nonogaki K. Dysglycemia and cardiovascular risk. J Am Coll Cardiol. 60,1121, 2012.
7．Nonogaki K. Serotonin conflict in sleep-feeding. Vitam Horm. 89, 223-239, 2012.
8．Nonogaki K. The relative contribution of hypothalamic neurons to the FoxO1-mediated regulation of feeding, body weight and hepatic glucose production. Comment on FoxO1 target Gpr17 activates AgRP neurons to regulate food intake. Cell, 149,1314-1326, 2012.
9．Nonogaki K. Does serotonin actually increase sleep ? Comment on Genetics of sleep and sleep disorders. Cell, 146,194-207, 2011.
10．Nonogaki K, Suzuki M, Sanuki M, Wakameda M, Tamari T. The contribution of serotonin 5-HT2C and melanocortin-4 receptors to the satiety signaling of glucagon-like peptide 1 and liragultide, a glucagon-like peptide 1 receptor agonist, in mice. Biochem Biophys Res Commun. 411,445-448, 2011
11．Nonogaki K, Suzuki M, Kanai N, Sumii M, Kaji T. Short-term effect of pitavastatin on the reactive hyperemic index in post-menopausal women with high levels in serum LDL-cholesterol. Int J Cardiol. 150,227-228, 2011.
12．Nonogaki K, Kaji T. Hypothalamic orexin and pro-opiomelanocortin activities are essential for the　anorexic effects of m-chlorophenylpiperazine in mice. Int J Neuropsychopharmacol. 13:1261-7, 2010.
13．Nonogaki K, Kaji T. Contribution of central SGK-1 to the acute phase responses of mice to social isolation. Front Biosci (Elite Ed).1:1355-61, 2010.
14．Nonogaki K, Kaji T, Ohba Y, Sumii M, Wakameda M, Tamari T. Serotonin 5-HT2C receptor-independent expression of hypothalamic NOR1, a novel modulator of food intake and energy balance, in mice. Biochem Biophys Res Commun. 386:311-5, 2009.
15．Nonogaki K, Ohba Y, Sumii M, Wakameda M, Tamari T. Novel modulators for body weight changes induced by fasting and re-feeding in mice. Biochem Biophys Res Commun. 378:249-54, 2009.
16．Nonogaki K, Ohba Y, Wakameda M, Tamari T. Fluvoxamine exerts anorexic effect in 5-HT2C receptor mutant mice with heterozygous mutation of beta-endorphin gene. Int J Neuropsychopharmacol. 12:547-52, 2009.
17．Nonogaki K, Ohba Y, Sumii M, Oka Y. Serotonin systems upregulate the expression of hypothalamic NUCB2 via 5-HT2C receptors and induce anorexia via a leptin-independent pathway in mice. Biochem Biophys Res Commun. 372:186-90, 2008.
18．Nonogaki K. 5-HT and NA Uptake Inhibitors and Appetite Regulation: The Role of the Central 5-HT Network. Immun Endoc & Metab Agents in Med Chem. 2008, 8, 303-310 review, 2008.
19．Nonogaki K, Ohba Y, Sumii M, Oka Y. Serotonin systems upregulate the expression of hypothalamic NUCB2 via 5-HT2C receptors and induce anorexia via a leptin-independent pathway in mice. Biochem Biophys Res Commun. 372:186-190, 2008.
20．Nonogaki K. Ghrelin and feedback systems. Vitam Horm,77:149-70, 2007. 21．Nonogaki K, Nozue K, Oka Y. Social isolation affects the development of obesity and type 2 diabetes in mice.Endocrinology.148:4658-66, 2007.
22．Heisler LK, Pronchuk N, Nonogaki K, Zhou L, Raber J, Tung L, Yeo GS, O'Rahilly S, Colmers WF, Elmquist JK, Tecott LH. Serotonin activates the hypothalamic-pituitary-adrenal axis via serotonin 2C receptor stimulation. J Neurosci.27:6956-64, 2007.
23．Nonogaki K, Tateishi K, Nonogaki N. Isn't this just snacking? The potential adverse effects of night-eating symptoms on treatment adherence and outcomes in patients with diabetes: response to Morse et al. Diabetes Care. 30:e38, 2007.
24．Nonogaki K, Nozue K, Kuboki T, Oka Y. Milnacipran, a serotonin and norepinephrine reuptake inhibitor, induces appetite-suppressing effects without inducing hypothalamic stress responses in mice. Am J Physiol Regul Integr Comp Physiol.292:R1775-81, 2007.
25．Nonogaki K, Nozue K, Oka Y. Increased hypothalamic 5-HT2A receptor gene expression and effects of pharmacologic 5-HT2A receptor inactivation in obese Ay mice. Biochem Biophys Res Commun.351:1078-82, 2006.